Global Cardiovascular Drug Market to Hit $116.3 Billion By 2010 Forecasts URCH Publishing
LONDON--The global cardiovascular drug market is forecast to expand to US$116.3 billion in 2010, says a new report from URCH Publishing, a leading provider of pharmaceutical industry business information.
The report, Cardiovascular Pharmaceutical Market Trends 2007 to 2010, which is published today, says that although there will be growth of 5.3% over the next four years, there will be a slowing of growth due to continued patent expires of major products. However, virtually all companies involved in this area will see solid sales growth of their cardiovascular portfolios. "Four of the top 10 cardiovascular companies in 2005 are forecast to grow their cardiovascular sales at a double-digit annual growth rate over the next five years," commented Steve Seget the report's author. "They are Sanofi-Aventis, Novartis, GlaxoSmithKline and Boehringer Ingelheim; however, Merck is forecast to see declining sales resulting in a fall from second to sixth place in the list of top cardiovascular companies by 2010".
The 112 page publication provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders. Other key findings from the report include:
* The global market for cardiovascular patients will increase to 251 million in 2010, with the greatest rate of growth forecast for the US market.
* The anti-hypertensives drug class dominates the global cardiovascular market with a market share of nearly 50%.
* Of the top 20 products by global cardiovascular sales in 2005, all 20 generated annual sales in excess of US$1 billion.
* The top 20 products in 2005 contributed sales of US$59.3 billion accounting for 66.1% of the total cardiovascular market.
* A total of 14 pharmaceutical companies were identified as having generated cardiovascular sales in excess of US$1 billion in 2005.
"Cardiovascular Pharmaceutical Market Trends 2007 to 2010 - Key market forecasts and growth opportunities" is available from URCH Publishing. Find more details at
http://www.urchpublishing.com/publications/therapeutic/ cardiovascular_pharmaceutical_00
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About URCH Publishing Ltd (http://www.urchpublishing.com)
URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry.
Press review copies may be available on request.
Contacts
URCH Publishing
Edwin Bailey, +44 (0) 20 7060 1099
service@urchpublishing.com
The report, Cardiovascular Pharmaceutical Market Trends 2007 to 2010, which is published today, says that although there will be growth of 5.3% over the next four years, there will be a slowing of growth due to continued patent expires of major products. However, virtually all companies involved in this area will see solid sales growth of their cardiovascular portfolios. "Four of the top 10 cardiovascular companies in 2005 are forecast to grow their cardiovascular sales at a double-digit annual growth rate over the next five years," commented Steve Seget the report's author. "They are Sanofi-Aventis, Novartis, GlaxoSmithKline and Boehringer Ingelheim; however, Merck is forecast to see declining sales resulting in a fall from second to sixth place in the list of top cardiovascular companies by 2010".
The 112 page publication provides an excellent overview to the current and future market dynamics and size for drug treatments for cardiovascular-related disorders. Other key findings from the report include:
* The global market for cardiovascular patients will increase to 251 million in 2010, with the greatest rate of growth forecast for the US market.
* The anti-hypertensives drug class dominates the global cardiovascular market with a market share of nearly 50%.
* Of the top 20 products by global cardiovascular sales in 2005, all 20 generated annual sales in excess of US$1 billion.
* The top 20 products in 2005 contributed sales of US$59.3 billion accounting for 66.1% of the total cardiovascular market.
* A total of 14 pharmaceutical companies were identified as having generated cardiovascular sales in excess of US$1 billion in 2005.
"Cardiovascular Pharmaceutical Market Trends 2007 to 2010 - Key market forecasts and growth opportunities" is available from URCH Publishing. Find more details at
http://www.urchpublishing.com/publications/therapeutic/ cardiovascular_pharmaceutical_00
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About URCH Publishing Ltd (http://www.urchpublishing.com)
URCH Publishing Ltd is an independent business information publisher dedicated to delivering quality information products to the global pharmaceuticals industry.
Press review copies may be available on request.
Contacts
URCH Publishing
Edwin Bailey, +44 (0) 20 7060 1099
service@urchpublishing.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.